 The study investigates the association between serum lipocalin, two levels and disease activity, markers of inflammation or metabolic disturbances in psoriatic patients, and finds that while lipocalin, two may be a marker of psoriasis and convey cardiovascular or metabolic risk, it is not a reliable indicator of inflammation, severity of psoriasis, or efficacy of anti psoriatic treatment. This article was authored by a baron, M. Slydeska, H. Myceliweak, and others.